Myriad Genetics
- Revenue$690.6 MFY, 2021
- Market Capitalization$1.5 B2022-06-29
OverviewSuggest Edit
Myriad Genetics is a genetic testing and precision medicine company. It specializes its products, capabilities, and expertise in three areas: oncology, women's health, and mental health. The company develops molecular diagnostic tests designed to analyze genes and their expression levels to assess an individual’s risk for developing disease, determine a patient’s likelihood of responding to a particular drug, or assess a patient’s risk of disease progression.
| Type | Public | |
| Founded | 1991 | |
| HQ | Salt Lake City, UT, US | Map |
| Website | myriad.com | |
| Employee Ratings | ||
| Overall Culture | B- | More |
Recent NewsAll News
- Myriad Genetics Issues Inaugural Environmental, Social and Governance Report
- Epic, Myriad Genetics collaborate on EHR integration for genetic testing
- Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
- Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
Key People/Management at Myriad Genetics
Paul J. Diaz
President & CEO
Eric Santa
Chief Growth Officer
Kevin R. Haas
Chief Technology Officer
Bryan Riggsbee
Chief Financial Officer
Jayne B. Hart
Chief People Officer
Pamela Wong
Chief Legal Officer
Myriad Genetics Office Locations
Myriad Genetics has offices in Salt Lake City, Austin, Mason, South San Francisco and in 7 other locations
Salt Lake City, UT, US (HQ)
320 Wakara Way
Austin, TX, US
3300 Duval Rd
Mason, OH, US
6960 Cintas Blvd
South San Francisco, CA, US
180 Kimball Way
South San Francisco, CA, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
41 Rue Camille Desmoulins
Myriad Genetics Financials and Metrics
Myriad Genetics Revenue
Myriad Genetics's revenue was reported to be $690.6 m in FY, 2021
| USD | |
|---|---|
Revenue (Q1, 2022) | 164.9m |
Gross profit (Q1, 2022) | 116.9m |
Gross profit margin (Q1, 2022), % | 70.9% |
Net income (Q1, 2022) | (20.5m) |
EBIT (Q1, 2022) | (25.6m) |
Market capitalization (29-Jun-2022) | 1.5b |
Closing stock price (29-Jun-2022) | 18.4 |
Cash (31-Mar-2022) | 165.2m |
EV | 1.4b |
Myriad Genetics's current market capitalization is $1.5 b.
Annual
Annual
Annual
| USD | FY, 2019 |
|---|---|
EV/EBIT | 288.5 x |
EV/CFO | 26.2 x |
Revenue/Employee | 327.3k |
Debt/Equity | 0.2 x |
Debt/Assets | 0.2 x |
Financial Leverage | 1.4 x |
P/E Ratio | 463.0 |
Myriad Genetics Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Counsyl | July 31, 2018 | $405.9 m |
| Myriad Women’s Health | May 29, 2018 | $408.6 m |
| Assurex Health, Inc. | August 04, 2016 | $225 m |
| Myriad Neuroscience | August 03, 2016 | $351.6 m |
| Sividon Diagnostics | May 31, 2016 | $56 m |
| Privatklinik Dr. Robert Schindlbeck | February 27, 2015 | $20.1 m |
| Crescendo Bioscience | February 04, 2014 | |
| Myriad Autoimmune | February 04, 2014 | $270 m |
| Rules-Based Medicine | April 27, 2011 | $80 m |
| Javelin Pharmaceuticals | December 18, 2009 | $95 m |
Myriad Genetics Revenue Breakdown
Myriad Genetics revenue breakdown by business segment: 96.5% from Molecular Diagnostic Testing and 3.5% from Other
Myriad Genetics Cybersecurity Score
Myriad Genetics Environment, Social & Governance (ESG) Ratings
Myriad Genetics Online and Social Media Presence
6.66k Twitter followers
Myriad Genetics has 6.66k Twitter Followers. The number of followers has increased 0.9% month over month and increased 2.3% quarter over quarter
Myriad Genetics's Trends
Twitter Engagement Stats for @myriadgenetics
17.8k
Tweets
1k
Following
6.7k
Followers
146
Tweets last 30 days
4.5
Avg. likes per Tweet
99.3%
Tweets with engagement
Myriad Genetics Company Culture
Overall Culture
B-
70/100
CEO Rating
D+
61/100
Compensation
B
75/100
Myriad Genetics News and Updates
June 28, 2022
Myriad Genetics Issues Inaugural Environmental, Social and Governance Report
SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable so…
June 28, 2022
Epic, Myriad Genetics collaborate on EHR integration for genetic testing
Myriad Genetics is working with Epic to integrate its genetic test technology into the electronic health record used by more than 600,000 physicians.
WHY IT MATTERS
The integration enables end-to-end workflows for healthcare providers to order Myriad tests and review their results directly within th…
June 23, 2022
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company, to integrate Myriad’s full line of genetic tests with Epic’s expan…
June 09, 2022
Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
SALT LAKE CITY, June 09, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation and growth plan during a fireside chat at the Goldman Sachs 43rd Annual Global H…
May 26, 2022
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and…
May 17, 2022
Shadowbox technology facilitated orders of Myriad Genetics germline diagnostic, increasing volume by more than 800%
SAN DIEGO, May 17, 2022 /PRNewswire/ -- Shadowbox, a leading innovator in healthcare automation solutions, is excited to announce the results of a case study with leading genetic testing company, Myriad Genetics, that not only eliminated cumbersome manual work, but also increased...
Myriad Genetics Blogs
May 18, 2022
The Next Wave of the Pandemic
When the Covid-19 pandemic first hit, many patients took what they thought would be a temporary break from preventive care visits to the doctor. However, more than two years later, people still aren’t coming in for their annual physicals and screenings at pre-pandemic levels. And with staff shortage…
May 17, 2022
New Guidelines from AUA and ASTRO Support Inclusion of Genomic Testing in Localized Prostate Cancer
By Thomas Slavin, M.D., chief medical officer, Myriad Genetics According to the American Cancer Society, in 2022 more than 268,000 men in the United States will be diagnosed with prostate cancer, making it the second most common cancer in men. Tragically, close to 35,000 men will die from prostate …
May 12, 2022
Making Genetic Testing More Inclusive
Myriad Genetics’ innovative approach to genetic testing gives more women the information they need to stay healthy. By FastCo Works For the past 30 years, Myriad Genetics has been involved in genetic testing to help women determine their risk of breast cancer. Typically, about 5% of women test posit…
April 23, 2022
The Future of Genetic Testing: How a Love of DNA Led to More Comprehensive Tests
For more than 30 years now, scientists at Myriad Genetics have been finding creative ways to coax new information out of human genes. The love for exploring the human genome has given us the foundation on which to build genetic tests that help people understand their risk of cancer, which mental hea…
March 22, 2022
During Women’s History Month, We’re Celebrating Women’s Contributions at Myriad Genetics
Throughout March we’re celebrating Women’s History Month, a recognition of the countless contributions women have made here in the U.S. and around the world. This year, the theme is “providing healing, promoting hope” — a concept that really resonates with our team and our push to deliver better hea…
March 21, 2022
New Enhancements to Noninvasive Prenatal Screening (NIPS)
Myriad Genetics was honored to participate in one of the most important conferences for Maternal Fetal Medicine specialists and other medical providers focused on the health of mothers, pregnancies, and babies. At the Society for Maternal-Fetal Medicine’s 42nd Annual Pregnancy Meeting, Myriad Geneti…
Myriad Genetics Frequently Asked Questions
When was Myriad Genetics founded?
Myriad Genetics was founded in 1991.
Who are Myriad Genetics key executives?
Myriad Genetics's key executives are Paul J. Diaz, Eric Santa and Kevin R. Haas.
How many employees does Myriad Genetics have?
Myriad Genetics has 2,400 employees.
What is Myriad Genetics revenue?
Latest Myriad Genetics annual revenue is $690.6 m.
What is Myriad Genetics revenue per employee?
Latest Myriad Genetics revenue per employee is $287.8 k.
Who are Myriad Genetics competitors?
Competitors of Myriad Genetics include Asuragen, Progenity and Foundation Medicine.
Where is Myriad Genetics headquarters?
Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.
Where are Myriad Genetics offices?
Myriad Genetics has offices in Salt Lake City, Austin, Mason, South San Francisco and in 7 other locations.
How many offices does Myriad Genetics have?
Myriad Genetics has 12 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies